Treasurer of the State of North Carolina Has $3.46 Million Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Treasurer of the State of North Carolina cut its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.2% in the fourth quarter, HoldingsChannel reports. The fund owned 28,068 shares of the specialty pharmaceutical company’s stock after selling 328 shares during the quarter. Treasurer of the State of North Carolina’s holdings in Jazz Pharmaceuticals were worth $3,457,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of JAZZ. Pacer Advisors Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 5.5% during the fourth quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock worth $272,713,000 after purchasing an additional 115,102 shares during the period. GW&K Investment Management LLC lifted its position in Jazz Pharmaceuticals by 26.6% in the 4th quarter. GW&K Investment Management LLC now owns 464,003 shares of the specialty pharmaceutical company’s stock worth $57,142,000 after buying an additional 97,589 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Jazz Pharmaceuticals by 501.4% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 112,055 shares of the specialty pharmaceutical company’s stock valued at $13,800,000 after acquiring an additional 93,422 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth $11,373,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Jazz Pharmaceuticals by 15.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 615,517 shares of the specialty pharmaceutical company’s stock worth $75,801,000 after acquiring an additional 83,807 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock opened at $101.55 on Thursday. The company has a market capitalization of $6.17 billion, a P/E ratio of 14.30, a P/E/G ratio of 1.04 and a beta of 0.42. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12 month low of $95.49 and a 12 month high of $148.06. The stock has a 50 day moving average of $128.56 and a two-hundred day moving average of $122.42.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on JAZZ shares. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Piper Sandler reiterated an “overweight” rating and issued a $176.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. Needham & Company LLC restated a “buy” rating and set a $210.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, April 10th. Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and lifted their price objective for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. Finally, JPMorgan Chase & Co. increased their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $187.71.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,140 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $137.81, for a total transaction of $157,103.40. Following the completion of the transaction, the chief accounting officer now owns 7,012 shares in the company, valued at $966,323.72. This trade represents a 13.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the sale, the chief executive officer now owns 439,744 shares in the company, valued at approximately $53,785,088.64. This represents a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 28,736 shares of company stock valued at $4,023,305 over the last ninety days. 4.20% of the stock is owned by company insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.